NAGE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Niagen Bioscience Inc (NAGE) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company shows strong financial growth, positive news catalysts, and a promising market expansion strategy. Despite neutral technical indicators and no proprietary trading signals, the positive sentiment from the new patent and financial performance outweighs the lack of immediate trading momentum.
The MACD is positive and expanding, indicating bullish momentum. RSI is neutral at 50.72, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support is at 4.821, with resistance at 5.355. The stock is trading near its pivot level of 5.088 in pre-market at 5.19.
Niagen Bioscience has secured a new U.S. patent for intravenous formulations, enhancing its competitive edge and intellectual property portfolio. The new IV products are available at over 1,200 clinics, facilitating market expansion and sales growth. Financial performance shows significant YoY growth in revenue (+32.86%), net income (+143.77%), and EPS (+150%).
No significant hedge fund or insider trading trends. Moving averages are bearish, and there is no recent congress trading data or proprietary trading signals.
In Q3 2025, revenue increased by 32.86% YoY to $33,986,000. Net income grew by 143.77% YoY to $4,578,000, and EPS rose by 150% YoY to 0.05. Gross margin improved slightly to 64.52%, up 1.62% YoY.
No recent analyst rating or price target changes available. Wall Street sentiment is neutral, with no significant pros or cons noted.
